<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01860196</url>
  </required_header>
  <id_info>
    <org_study_id>MT_IT_009</org_study_id>
    <nct_id>NCT01860196</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Meditoxin® Injection for Cervical Dystonia in Adults With Cerebral Palsy</brief_title>
  <acronym>ATHETOID_CD</acronym>
  <official_title>A Placebo Controlled, Cross-over, Double Blind, Randomized, Clinical Trial to Compare the Efficacy and Safety of Meditoxin® Injection for Cervical Dystonia in Adults With Cerebral Palsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <brief_summary>
    <textblock>
      This study aimed to compare the efficacy and safety of Meditoxin® injection for cervical
      dystonia in adults with cerebral palsy. It is a placebo controlled, Cross-over, Double blind,
      Randomized, Clinical trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)</measure>
    <time_frame>0, 16, 32 weeks</time_frame>
    <description>Change of Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) from baseline TWSTRS at 0 week.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain in numerical rating scale (NRS)</measure>
    <time_frame>Every 4 weeks, up to 32 weeks</time_frame>
    <description>Pain in numerical rating scale (NRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Japanese Orthopaedic Association (JOA) score</measure>
    <time_frame>Every 4 weeks, up to 32 weeks</time_frame>
    <description>Change of Japanese Orthopaedic Association (JOA) score from baseline Japanese Orthopaedic Association (JOA) score at 0 week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Goal attainment scale</measure>
    <time_frame>4, 12, 20, 28 weeks</time_frame>
    <description>Goal attainment scale of subjective improvement from the baseline status at 0 and 16 weeks.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse effect</measure>
    <time_frame>Every 4 weeks, up to 32 weeks</time_frame>
    <description>vital sign, adverse effect</description>
  </other_outcome>
  <other_outcome>
    <measure>computed tomography (CT)</measure>
    <time_frame>0, 32 weeks</time_frame>
    <description>Change of cervical spine computed tomography (CT) from baseline CT at 0 week.</description>
  </other_outcome>
  <other_outcome>
    <measure>videofluoroscopic swallowing study (VFSS)</measure>
    <time_frame>0, 12, 28 weeks</time_frame>
    <description>Change of videofluoroscopic swallowing study (VFSS) from baseline VFSS at 0 week.</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood/Urine laboratory tests</measure>
    <time_frame>0, 16, 32 weeks</time_frame>
    <description>Hemoglobin, Hematocrit, RBC, WBC, WBC different cell count, Platelet
Alkaline phosphatase, BUN, Creatinine, SGPT(ALT), SGOT(AST), Albumin, Total protein, Total bilirubin, Uric acid, Glucose, Cholesterol, LDH, Na, Ca, K, Cl
Urine pH, Protein, Glucose, Bilirubin, Blood, WBC</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Adult Cerebral Palsy</condition>
  <arm_group>
    <arm_group_label>Treatment-Placebo Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment on 0 day Placebo at 5th week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Treatment Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo on 0 day Treatment at 5th week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meditoxin</intervention_name>
    <arm_group_label>Treatment-Placebo Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <arm_group_label>Placebo-Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult cerebral palsy patients over 20 years old

          -  Clinically diagnosed for cervical dystonia more than a year ago

          -  No improvement with antispasmodics for the last month

          -  Actively participated and gave informed consent

        Exclusion Criteria:

          -  Allergic to the botulinum toxin

          -  Limited range of motion in cervical spine

          -  Patients with fever, infection, cancer, uncontrollable seizure

          -  Generalized neuromuscular junction disease patients

          -  Pregnant or breast feeding women, or anticipating pregnancy until 12 weeks after the
             study stopped

          -  Patients enrolled in other studies

          -  History of dose change in 4 weeks: antispasmodics, benzodiazepine, anticholinergics

          -  Botulinum toxin injection history in 6 months

          -  Previous history of intrathecal baclofen, selective peripheral denervation, deep brain
             stimulation

          -  Otherwise clinically non-eligible patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2013</study_first_submitted>
  <study_first_submitted_qc>May 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2013</study_first_posted>
  <last_update_submitted>August 19, 2017</last_update_submitted>
  <last_update_submitted_qc>August 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Keewon Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Cerebral Palsy</mesh_term>
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Torticollis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 8, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

